| | | Fierce will be taking a long weekend and won’t be sending its publications on Monday, July 4th. This includes FierceBiotech, FiercePharma and FierceMedicalDevices, as well as FierceAnimalHealth, FierceBiotechIT and FiercePharmaMarketing, which will arrive Tuesday instead. Thanks for reading, and enjoy the weekend! | |
|
Top Stories Friday, July 1, 2016 He’s only been Arena’s president and CEO for two months, but biotech vet Amit Munshi is wasting no time getting to know his new staff as the company announces a culling of 100 U.S. workers and (another) shift in focus. Friday, July 1, 2016 Déjà vu at Ampio Pharmaceuticals as its shares tumbled by 61% yesterday after it posted new data showing its knee osteoarthritis drug once again failed to hit its primary endpoint. Friday, July 1, 2016 Tiny Californian biotech Altos Therapeutics has won the backing of Japanese Big Pharma Takeda to help it move forward with its one and only candidate--with a sweetened buyout deal also on the cards. Thursday, June 30, 2016 Opko Health has paid up a little--very little, in fact--to get what it sees as the most advanced clinical candidate in the new class of GLP-1/glucagon receptor dual agonists. It did a $60 million, all-stock deal to acquire microcap Transition Therapeutics. Thursday, June 30, 2016 Merck KGaA, Pfizer invest in cancer biotech, Evotec teams up for NASH project and Cytune bags cash for oncology trial. And more. Thursday, June 30, 2016 FDA named Dr. Richard Pazdur as its interim head for the Oncology Center of Excellence. Plus more hirings, firings and retirings throughout the industry.
| | | Former Biogen SVP of corporate affairs Daniel McIntyre has been snapped up by Flagship Ventures as a partner, strategic communication. Release San Diego cancer biotech Ignyta has secured a $42 million term loan facility from Silicon Valley Bank and Oxford Finance. Statement Boulder, CO-based Array BioPharma has submitted an NDA for its experimental binimetinib in patients with advanced NRAS-mutant melanoma to the FDA. Release Australia’s Mesoblast has announced plans for an early data readout on its Phase III chronic heart failure trial. Statement Cambridge, MA-based Alnylam posts new results from its investigational RNAi programs in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy and Cardiomyopathy. Release Flagship Ventures has set out to raise a $350 million opportunities fund. SEC filing Austin, TX-based XBiotech has signed an agreement with Megapharm to market Xilonix in Israel. Release | |
|
Resources Sponsored by: SDC
Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Covance
Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today! Sponsored by: Veeva Systems
Gartner research on short- and long-term strategies for IDMP compliance.
|
|
